Clayton Foundation For Research
- Assets
- $144.9m
- Revenue
- $11.0m
- Investments
- $0.0
- Employees
- 55
- Location
- Houston, TX
- Founding
- 07/1966
- Data as of
- 12/2021
- EIN
- 74-1541767
Organization Overview
Clayton Foundation For Research is located in Houston, TX. The organization was established in 1966. According to its NTEE Classification (H99) the organization is classified as: Medical Research N.E.C., under the broad grouping of Medical Research and related organizations. As of 12/2021, Clayton Foundation For Research employed 55 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Clayton Foundation For Research is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2021, Clayton Foundation For Research generated $11.0m in total revenue. This represents relatively stable growth, over the past 7 years the organization has increased revenue by an average of 2.4% each year. All expenses for the organization totaled $10.3m during the year ending 12/2021. While expenses have increased by 1.3% per year over the past 7 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2021
Describe the Organization's Mission:
Part 3 - Line 1
THE PRIMARY MISSION IS TO CONDUCT MEDICAL RESEARCH IN CONJUNCTION WITH HOSPITALS FOR THE PURPOSE OF DISCOVERING THE CAUSE, PREVENTION AND CURE OF DISEASES FOR THE BENEFIT OF MANKIND.
Describe the Organization's Program Activity:
Part 3 - Line 4a
A RESEARCH PROJECT AT BAYLOR COLLEGE OF MEDICINE IN GENE AND PROTEIN THERAPY FOCUSES ON INAPPROPRIATE CELL DIVISION AND CELL DEATH WITHIN THE HUMAN BODY. MUCH OF THE WORK IS DEVOTED TO INTTAOCULARANGIOGENESIS, WITH PARTICULAR ATTENTION TO: 1) THE SIGNALS THAT CONTROL THIS PROCESS, 2) THE DEVELOPMENT OF ANIMAL MODELS OF HUMAN OCULAR DISEASE, AND 3) DEVELOPMENT OF POTENTIAL THERAPIES. PATENT APPLICATIONS HAVE BEEN FILED BY RDF, ONE OF THE FOUNDATION'S SUPPORTING ENTITIES, ON SEVERAL DISCOVERIES ARISING OUT OF THIS RESEARCH. LICENSING EFFORTS BY RDF HAVE RESULTED IN A LICENSE TO A COMMERCIAL COMPANY THAT, USING PROJECT TECHNOLOGY, HAS SUCCESSFULLY COMPLETED A PHASE I HUMAN CLINICAL TRIAL WITH GENE THERAPY TO TREAT WET AGE-RELATED MACULAR DEGENERATION. THE COMPANY ALSO HAS COMPLETED PRE-CLINICAL WORK AND NOW IS SEEKING REGULATORY APPROVAL FOR INITIATION OF HUMAN PHASE I/II CLINICAL TRIAL TO INHIBIT NEOVASCULARIZATION OF CORNEAS FOLLOWING TRANSPLANTATION.
HUMAN MONOCYTROPIC EHRLICHIOSIS IS AN EMERGING TICK-BORNE HUMAN DISEASE IN THE UNITED STATES CAUSED BY EHRLICHIA CHAFFEENSIS. CANINE MONOCYTIC EHRLICHIOSIS, CAUSED BY E. CANIS IS A SERIOUS DISEASE OF CANINES AND IS OF COMPARATIVE MEDICAL IMPORTANCE. E, CANIS INFECTIONS HAVE ALSO RECENTLY EMERGED IN HUMANS. THERE IS A NEED FOR EFFECTIVE VACCINES, SENSITIVE POINT-OF-CARE AND LABORATORY BASED DIAGNOSTICS, AND NEW GENERATION THERAPEUTICS. A RESEARCH PROGRAM AT THE UNIVERSITY OF TEXAS MEDICAL BRANCH, GALVESTON IS DIRECTED TOWARD ACHIEVING THE OVERALL GOAL OF THE DEVELOPMENT OF VACCINES AND DIAGNOSTICS FOR THE EHRLICHIA. RESEARCH TO DATE ON THIS PROJECT HAS RESULTED IN A NUMBER OF PATENT APPLICATIONS AND ISSUED PATENTS, SEVERAL LICENSES, AND DIAGNOSITIC PRODUCTS THAT ARE MARKETED BY COMMERCIAL COMPANIES.
IN A RESEARCH PROGRAM AT THE UNIVERSITY OF TEXAS AT AUSTIN, NEW INSIGHTS INTO THE NATURE OF IMMUNE RESPONSES HAS ENABLED THE DISCOVERY OF SERUM ANTIBODY METHODOLOGIES GIVING RISE TO, AMONG OTHER THINGS, ENGINEERED AGLYCOSYLATED ANTIBODIES THAT DISPLAY INCREASED POTENCY TOWARDS KILLING CANCER CELLS, PROVIDING NEW BIOLOGICAL DRUGS. IN ADDITION THE PROGRAM HAS DEVELOPED ENGINEERED ANTIBODIES WITH EXTENDED HALF-LIFE, WHICH HAVE BROAD REACHING APPLICATIONS AND SHOULD ALLOW TO REDUCE COSTS OF MONOCLONAL ANTIBODY THERAPEUTICS. SEVERAL PATENT APPLICATIONS HAVE BEEN FILED BY RDF, WITH SEVERAL ISSUED PATENTS AND LICENSES TO COMMERCIAL COMPANIES.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Jarred W Sloan Trustee, President, Treasurer | OfficerTrustee | 20 | $240,518 |
Robert L Evans Assistant Treasurer | Officer | 40 | $194,400 |
Robert M Wallace Trustee, Vice President | OfficerTrustee | 20 | $178,465 |
Kimberly A Shipley Assistant Secretary | Officer | 40 | $162,400 |
Joshua T Chang Project Researcher | 40 | $128,581 | |
Lawrence H Cheung Project Researcher | 40 | $109,633 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $7,250,000 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $0 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $7,250,000 |
| Total Program Service Revenue | $0 |
| Investment income | $1,635,048 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $133,161 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $1,964,496 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $10,982,705 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $50,500 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $1,507,867 |
| Compensation of current officers, directors, key employees. | $258,606 |
| Compensation to disqualified persons | $629,163 |
| Other salaries and wages | $2,817,768 |
| Pension plan accruals and contributions | $372,031 |
| Other employee benefits | $1,365,280 |
| Payroll taxes | $212,250 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $791 |
| Fees for services: Accounting | $56,978 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $337,544 |
| Fees for services: Other | $13,900 |
| Advertising and promotion | $0 |
| Office expenses | $62,742 |
| Information technology | $0 |
| Royalties | $0 |
| Occupancy | $363,600 |
| Travel | $7,555 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $0 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $29,408 |
| Insurance | $224,287 |
| All other expenses | $102,524 |
| Total functional expenses | $10,317,749 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $1,775,261 |
| Savings and temporary cash investments | $0 |
| Pledges and grants receivable | $0 |
| Accounts receivable, net | $270,377 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $175,385 |
| Net Land, buildings, and equipment | $145,430 |
| Investments—publicly traded securities | $112,865,433 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $29,680,108 |
| Total assets | $144,911,994 |
| Accounts payable and accrued expenses | $5,575,165 |
| Grants payable | $0 |
| Deferred revenue | $0 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $0 |
| Total liabilities | $5,575,165 |
| Net assets without donor restrictions | $97,112,182 |
| Net assets with donor restrictions | $42,224,647 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $144,911,994 |
Grants Awarded
Over the last fiscal year, Clayton Foundation For Research has awarded $20,000 in support to 2 organizations.
| Grant Recipient | Amount |
|---|---|
Austin, TX PURPOSE: Gen Purpose | $10,000 |
Baton Rouge, LA PURPOSE: Gen Purpose | $10,000 |
Grants Recieved
Over the last fiscal year, we have identified 1 grants that Clayton Foundation For Research has recieved totaling $5,500,000.
| Awarding Organization | Amount |
|---|---|
Research Development Foundation Carson City, NV PURPOSE: General Support | $5,500,000 |
Endowment Analysis
| Beg. Balance | $39,166,467 |
| Ending Balance | $39,166,467 |
Peer Organizations
| Organization Name | Assets | Revenue |
|---|---|---|
Clayton Foundation For Research Houston, TX | $144,911,994 | $10,982,705 |
Biomedical Research Institute Of New Mexico Albuquerque, NM | $13,199,153 | $8,153,350 |
Kidney Cancer Association Houston, TX | $23,316,300 | $6,390,706 |
Fractionation Research Inc Stillwater, OK | $7,018,117 | $4,169,009 |
Project Mend San Antonio, TX | $5,310,736 | $1,583,732 |
Wilderness Medical Society Inc Austin, TX | $2,806,544 | $1,840,089 |
Thomas N Lynn Institute For Healthcare Research Inc Oklahoma City, OK | $12,004,114 | $988,065 |
American Orthodontic Society Inc Grapevine, TX | $422,038 | $863,139 |
Restless Legs Syndrome Foundation Inc Austin, TX | $795,669 | $944,438 |
Social And Health Research Center Inc San Antonio, TX | $396,348 | $793,036 |
Baromedical Research Institute Ltd New Orleans, LA | $404,641 | $180,263 |
Human Proteome Organization Hupo Houston, TX | $683,130 | $537,131 |